In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now. In this piece, we take a closer look at Doximity Inc. (NYSE:DOCS) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Artificial intelligence is no longer limited to chatbots, digital advertising and Silicon Valley experiments. It is moving into hospitals, laboratories and pharmaceutical research, where algorithms are helping scientists discover potential medicines, interpret medical images, analyze genetic information and identify treatments suited to individual patients.

Interestingly, the termx term “artificial intelligence” was introduced in 1956, but medical AI took decades to become commercially practical. Modern healthcare systems now generate enormous amounts of clinical, imaging and genomic data—the exact type of information machine-learning models are designed to analyze.

Why Medicine Could Be AI’s Next Major Market

Drug development has traditionally required years of research, costly clinical trials and thousands of unsuccessful experiments. AI drug discovery platforms cannot eliminate those risks, but they can help researchers screen molecules, predict biological interactions and prioritize the most promising candidates before expensive trials begin.

Medical imaging has also become one of the earliest real-world applications of artificial intelligence in healthcare. AI-powered diagnostics can assist doctors in detecting abnormalities, improving image quality and prioritizing urgent cases. Meanwhile, precision medicine platforms are using clinical and genomic data to help match patients with more appropriate treatments.

These developments have encouraged investors to search for the best AI healthcare stocks, AI biotech stocks and medical AI companies positioned to benefit from the industry’s long-term expansion.

A Low Share Price Does Not Always Mean Cheap

A stock trading below $10 may look affordable, but it can still be overvalued if the company generates little revenue, loses money and repeatedly issues new shares. On the other hand, a profitable healthcare technology company trading above $50 may be undervalued when its earnings, cash flow and competitive advantages support a higher valuation.

The most attractive cheap AI medicine stocks therefore combine genuine medical applications with reasonable valuations, sufficient cash reserves, improving financial performance and meaningful long-term growth opportunities.

Finding the Best AI Medicine Stocks

This ranking evaluates NYSE- and Nasdaq-listed companies based on their AI exposure, valuation, revenue growth, financial strength, clinical potential and competitive position. Higher-risk companies were penalized for heavy losses, shareholder dilution, limited cash runways and uncertain paths to profitability.

The countdown begins with the most speculative AI medicine stock at No. 10 and ends with the strongest overall risk-adjusted pick at No. 1. These companies operate across AI drug discovery, precision medicine, genomic analysis, medical imaging, digital health and clinical research—some of the most promising fields where artificial intelligence could reshape modern healthcare.

CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.

Our Methodology

For the 10 Cheap AI Medicine Stocks That Could Make You a Millionaire, we ranked each company based on its valuation, medical AI exposure, revenue growth, financial strength, clinical potential and overall investment risk.

10 Best Cheap AI Medicine Stocks to Buy Now

10. Doximity Inc. (NYSE:DOCS)

Doximity, Inc. (NYSE: DOCS) opens the ranking as one of the most established digital platforms serving American physicians and healthcare professionals.

The platform is sometimes described as a professional network for doctors, but its business now extends well beyond professional profiles and medical news. It provides secure patient communication, telehealth, clinical collaboration, electronic prescribing and workflow-management products.

Artificial intelligence is becoming increasingly important to that ecosystem. The company has introduced AI-powered clinical search, automated note-taking and tools that can assist physicians in preparing medical documentation and patient communications.

That is strategically significant because the company does not need to build a healthcare audience from scratch. It already has an extensive network of medical professionals who can adopt these artificial intelligence healthcare tools within workflows they use regularly.

More than 800,000 active prescribers reportedly used its workflow tools during the fiscal fourth quarter. Nearly half of those providers also used its clinical AI products, while prompts per user almost doubled between January and April.

However, the business has recently struggled to convert rapidly rising AI engagement into equally impressive revenue growth. Fiscal fourth-quarter revenue increased only 5% year over year to approximately $145.4 million. Management’s fiscal 2027 revenue forecast of between $664 million and $676 million also came in below Wall Street expectations.

The company remains highly profitable compared with most emerging healthcare AI companies, but its near-term growth profile is no longer as strong as it was in previous years. That is why it enters the list at No. 10 rather than challenging the faster-growing diagnostic and medical-imaging businesses.

The long-term opportunity is still attractive. If clinical AI becomes a routine tool for physicians, the company’s existing professional network could become an exceptionally effective distribution channel. Investors must simply wait for rising AI usage to produce a more visible financial contribution.

YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.